The specter of pandemics and the relentless rise of antimicrobial resistance have thrust the once-niche sector of biosafety and infection control into the global spotlight. For investors, this represents a
The specter of pandemics and the relentless rise of antimicrobial resistance have thrust the once-niche sector of biosafety and infection control into the global spotlight. For investors, this represents a